Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae-Reference-Cited by-同舟云学术

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

Published:2018-12 Issue:12 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Scangarella-Oman Nicole E.¹,Hossain Mohammad¹,Dixon Paula B.²,Ingraham Karen¹,Min Sharon¹,Tiffany Courtney A.¹,Perry Caroline R.¹,Raychaudhuri Aparna¹,Dumont Etienne F.¹,Huang Jianzhong¹,Hook Edward W.²,Miller Linda A.¹

Affiliation:

1. GlaxoSmithKline, Upper Providence, Pennsylvania, USA

2. University of Alabama at Birmingham, Birmingham, Alabama, USA

Abstract

We evaluated microbiological correlates for the successful treatment of Neisseria gonorrhoeae isolates from a phase 2 study of gepotidacin, a novel triazaacenaphthylene antibacterial, for therapy of uncomplicated urogenital gonorrhea. Culture, susceptibility testing, genotypic characterization, and frequency of resistance (FoR) were performed for selected isolates.

Funder

GlaxoSmithKline

HHS | Biomedical Advanced Research and Development Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01221-18

Reference32 articles.

1. Centers for Disease Control and Prevention. 2017. Reported STDs in the United States 2016. High burden of STDs threaten millions of Americans. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov/nchhstp/newsroom/docs/factsheets/STD-Trends-508.pdf.

2. Centers for Disease Control and Prevention. 2017. Sexually transmitted diseases surveillance 2016. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov/std/stats16/CDC_2016_STDS_Report-for508WebSep21_2017_1644.pdf.

3. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

4. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action

5. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alternative drugs for the treatment of gonococcal infections: old and new;Expert Review of Anti-infective Therapy;2024-09-10

2. Optimization of Ethoxzolamide Analogs with Improved Pharmacokinetic Properties for In Vivo Efficacy against Neisseria gonorrhoeae;Journal of Medicinal Chemistry;2024-08-14

3. In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions;Journal of Antimicrobial Chemotherapy;2024-07-08

4. The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains—phenotypic, genetic and reference genome characterization;Journal of Antimicrobial Chemotherapy;2024-06-21

5. Management of Neisseria gonorrhoeae infection: from drug resistance to drug repurposing;Expert Opinion on Therapeutic Patents;2024-06-02